Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX – Get Rating) – Analysts at HC Wainwright issued their Q1 2023 earnings estimates for shares of Lineage Cell Therapeutics in a research note issued to investors on Friday, March 10th. HC Wainwright analyst J. Pantginis forecasts that the company will post earnings of ($0.03) per share for the quarter. The consensus estimate for Lineage Cell Therapeutics’ current full-year earnings is ($0.17) per share. HC Wainwright also issued estimates for Lineage Cell Therapeutics’ FY2027 earnings at ($0.01) EPS.
Lineage Cell Therapeutics Price Performance
Lineage Cell Therapeutics stock opened at $1.43 on Monday. The stock has a market capitalization of $243.07 million, a price-to-earnings ratio of -9.53 and a beta of 1.66. Lineage Cell Therapeutics has a 1 year low of $1.02 and a 1 year high of $1.79.
Institutional Inflows and Outflows
Lineage Cell Therapeutics Company Profile
Lineage Cell Therapeutics, Inc operates as a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, neurological conditions associated with demyelination, and aiding the body in detecting and combating cancer. The company’s programs are based on two core proprietary technology platforms: cell replacement and cell and drug delivery.
- Get a free copy of the StockNews.com research report on Lineage Cell Therapeutics (LCTX)
- What the SVB Financial Collapse Means for U.S. Banks
- MarketBeat Week in Review – 3/6 – 3/10
- 2 Offshore Drilling Stocks Set to Extract Big Profits
- Three Staples Stocks With Double-Digit Upside Ahead
- Can Investors Trust Consumers to Lift American Outdoor Brands?
Receive News & Ratings for Lineage Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lineage Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.